Galicaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
RCT-2100 is under development for the treatment of cystic fibrosis (CF). The therapeutic candidate is an mRNA, encoding cystic fibrosis transmembrane conductance regulator (CFTR). It is administered ...
Cystic fibrosis is a genetic disorder that affects various organs, including the lungs and digestive system. Medications are important for managing symptoms, but there is currently no cure for the ...
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
What's better than one dual meet? Two, of course. General McLane wrestling hosted the Corry boys and girls for a doubleheader Thursday on "Takedown Cystic Fibrosis" night.
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
GlobalData on MSN13d
Vertex secures two FDA wins for cystic fibrosis, both with boxed warningsVertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
LCI proves valuable in monitoring ETI therapy effectiveness for cystic fibrosis patients with minimal FEV1 changes, detecting ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Reading Eagle on MSN13h
Newsmakers for January 5READING HOSPITAL FOUNDATION Five Berks County professionals have been added to the Reading Hospital Foundation’s board of directors. Brian Boland, Esq., Dr. Anthony Donato, Kristi Gage-Linderman, P.
Zacks.com on MSN13d
Vertex Secures FDA Approval for New Cystic Fibrosis Drug AlyftrekThe FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback